From Pandemic Urgency to Practical Impact: How Diagnostics Investment Priorities Are Evolving
Speed still matters, but there’s been a shift in the industry. It’s not enough to be scientifically sound. Now, practicality is of utmost importance.
Dr. Jamie Platt</a> is CEO of <a href=https://medcitynews.com/author/jplatt/"https://www.pictordx.com/">Pictor and has more than 20 years of experience in genomics and molecular diagnostics. She has led the development and commercialization of high-complexity diagnostic tests globally and serves on the boards of DxTerity and bioAffinity Technologies. Jamie is a recognized voice in the diagnostics field, focused on advancing clinically meaningful, accessible testing that delivers real-world value for laboratories and health systems." />
Speed still matters, but there’s been a shift in the industry. It’s not enough to be scientifically sound. Now, practicality is of utmost importance.